baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BVT Call 165 PGR 20.09.2024/ DE000VM7PCY7 /

5/17/2024 8:04:39 PM	Chg.+0.150	Bid9:59:42 PM	Ask9:59:42 PM	Underlying	Strike price	Expiration date	Option type
4.530EUR	+3.42%	- Bid Size: -	- Ask Size: -	Progressive Corporat...	165.00 USD	9/20/2024	Call

GlobeNewswire 5/18 Intercept Presents New Data Demonstrating the Impact of OCA-Bezafibrate Combination Therapy on ALP a...

GlobeNewswire 5/16 BMW unveils The BMW XM Mystique Allure, a one-of-a-kind luxury vehicle inspired by the iconic superm...

GlobeNewswire 5/15 Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III P...

TeleTrader 5/15 Slovakian opposition denies connection to Fico's attack

GlobeNewswire 5/15 Progressive Reports April 2024 Results

GlobeNewswire 5/14 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment...

GlobeNewswire 5/13 Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Ap...

GlobeNewswire 5/13 BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transt...

GlobeNewswire 5/13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...

GlobeNewswire 5/9 Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st ...

GlobeNewswire 5/9 Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate...

GlobeNewswire 5/8 Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Plan...

GlobeNewswire 5/7 MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-1...

GlobeNewswire 5/6 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...

GlobeNewswire 5/4 The National Fire Sprinkler Association's Class of 2024: Honoring Fire Sprinkler Industry Greats

GlobeNewswire 5/2 PyroGenesis Announces 28-Day Lab Strength Tests Achieve Up to 99.56% Above Compressive Strength Targ...

GlobeNewswire 5/1 Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 A...

GlobeNewswire 5/1 Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 ...

GlobeNewswire 5/1 Opthea Announces Upcoming Presentations at the Retina World Congress 2024

GlobeNewswire 5/1 Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evalu...

GlobeNewswire 5/1 TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

GlobeNewswire 4/30 Progressive Announces Investor Relations Call

GlobeNewswire 4/25 Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Re...

GlobeNewswire 4/25 Opthea to Present at the OIS Retina Innovation Summit at ARVO

TeleTrader 4/25 Merck's Q1 sales rise by 9% to $15.8 billion

BVT Call 165 PGR 20.09.2024/ DE000VM7PCY7 /

If you wish to receive reply to your feedback, please provide your email address.